TipRanks
Advertisement
Advertisement

CNTX Stock Latest News

Context Therapeutics doses first patient in CT-202 trial
The FlyContext Therapeutics doses first patient in CT-202 trial
1M ago
CNTX
Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
PremiumRatings
Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
2M ago
CNTX
Context downgraded to Market Perform from Outperform at LifeSci Capital
PremiumThe Fly
Context downgraded to Market Perform from Outperform at LifeSci Capital
3M ago
CNTX
Context Therapeutics price target lowered to $3 from $4 at Citizens
PremiumThe Fly
Context Therapeutics price target lowered to $3 from $4 at Citizens
3M ago
CNTX
Analyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver
PremiumRatings
Analyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver
3M ago
CNTX
Analyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202
PremiumRatingsAnalyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202
3M ago
CNTX
Context Therapeutics reports Q2 EPS (15c), consensus (9c)
Premium
The Fly
Context Therapeutics reports Q2 EPS (15c), consensus (9c)
3M ago
CNTX
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
Premium
Company Announcements
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
3M ago
8K
CNTX
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
PremiumCompany Announcements
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
3M ago
8K
CNTX
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
PremiumCompany Announcements
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
3M ago
CNTX
Context Therapeutics Shareholders Approve Stock Increase and Directors
PremiumCompany Announcements
Context Therapeutics Shareholders Approve Stock Increase and Directors
4M ago
8K
CNTX
Context Therapeutics price target lowered to $4 from $8 at Maxim
PremiumThe Fly
Context Therapeutics price target lowered to $4 from $8 at Maxim
4M ago
CNTX
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
PremiumRatingsBoris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
4M ago
CNTX
Context Therapeutics selloff brings buying opportunity, says JonesResearch
Premium
The Fly
Context Therapeutics selloff brings buying opportunity, says JonesResearch
4M ago
CNTX
ZYME
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
Premium
Ratings
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
4M ago
CNTX
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
PremiumThe Fly
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
4M ago
CNTX
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
PremiumCompany Announcements
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
4M ago
8K
CNTX
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
PremiumThe Fly
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
4M ago
CNTX
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
PremiumRatings
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
5M ago
CNTX
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
PremiumRatingsAnalyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
5M ago
CNTX
Context Therapeutics Secures Full Rights to Antibody Assets
Premium
Company Announcements
Context Therapeutics Secures Full Rights to Antibody Assets
5M ago
8K
CNTX
Context Therapeutics enters license agreement amendment with BioAtla
Premium
The Fly
Context Therapeutics enters license agreement amendment with BioAtla
5M ago
BCAB
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >